Tango Therapeutics, Inc.
TNGX
Rank in Stocks
#4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Share Price
$27.18
Last synced: 2026-07-31
Market Cap
$3.38B
Change (1 day)
-1.41%
Change (1 year)
202.34%
Country
US
Trade Tango Therapeutics, Inc. (TNGX)
Category
Healthcare
P/E ratio for Tango Therapeutics, Inc. (TNGX)
P/E ratio as of October 2026 TTM: -26.11
According to Tango Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -26.11. At the end of 2023 the company had a P/E ratio of -9.20.
P/E ratio history for Tango Therapeutics, Inc. from 2019 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -26.11 | 907.95% |
| 2024 | -2.59 | -71.85% |
| 2023 | -9.20 | 56.35% |
| 2022 | -5.89 | -49.56% |
| 2021 | -11.67 | 65.65% |
| 2020 | -7.04 | 8.00% |
| 2019 | -6.52 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -210.25% |
US
|
|
| -28.36 | 8.63% |
US
|
|
| -24.57 | -5.90% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -216.18% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.